Date | Price Target | Rating | Analyst |
---|---|---|---|
2/14/2024 | $305.00 → $300.00 | Buy | Needham |
2/14/2024 | $315.00 → $240.00 | Overweight → Equal Weight | Wells Fargo |
1/24/2024 | $311.00 → $276.00 | Buy → Neutral | UBS |
12/20/2023 | $311.00 | Overweight | Cantor Fitzgerald |
12/7/2023 | $283.00 | Mkt Perform → Outperform | Raymond James |
9/6/2023 | $360.00 | Buy | HSBC Securities |
7/27/2023 | $327.00 | Sector Outperform | Scotiabank |
7/24/2023 | $346.00 → $335.00 | Buy | UBS |
4 - BIOGEN INC. (0000875045) (Issuer)
4 - BIOGEN INC. (0000875045) (Issuer)
4 - BIOGEN INC. (0000875045) (Issuer)
CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- The Biogen Inc. (NASDAQ:BIIB) Board of Directors (the "Board") today announced the appointments of two new independent directors, Lloyd B. Minor, M.D., effective October 1, 2024, and Sir Menelas (Mene) Pangalos, Ph.D., effective January 1, 2025. Dr. Minor is currently the Dean of the Stanford University School of Medicine and Vice President for Medical Affairs at Stanford University, and Prof Sir Pangalos was most recently Executive Vice President of Biopharmaceuticals R&D at AstraZeneca until his retirement in April 2024. "We welcome Lloyd and Mene to our Board as they add significant experience and proven track records in leading R&D
Positive study demonstrates the potential for investigational higher dose nusinersen regimen to advance the treatment of SMA; Biogen plans to submit for regulatory approval of this investigational dose regimenHigher dose nusinersen regimen showed statistically significant improvement compared to a prespecified matched sham control groupAmong key measures of clinical efficacy, higher dose regimen showed positive trends compared to the approved dosing regimen CAMBRIDGE, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced positive, topline data from the pivotal cohort (Part B) of the Phase 2/3 DEVOTE study evaluating the safety and efficacy of a higher dose re
FOR GLOBAL MEDIA AND JOURNALISTS OUTSIDE THE EMEA REGION In Great Britain, lecanemab is indicated for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease (AD) in adult patients that are apolipoprotein E ε4 (ApoE ε4)* heterozygotes or non-carriers1 Great Britain becomes the first country in Europe to authorize the medicine, which targets an underlying cause of AD1 TOKYO and CAMBRIDGE, Mass., Aug. 22, 2024 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ", Biogen", ))) announced today that the humanized amyloid-be
Needham reiterated coverage of Biogen with a rating of Buy and set a new price target of $300.00 from $305.00 previously
Wells Fargo downgraded Biogen from Overweight to Equal Weight and set a new price target of $240.00 from $315.00 previously
UBS downgraded Biogen from Buy to Neutral and set a new price target of $276.00 from $311.00 previously
8-K - BIOGEN INC. (0000875045) (Filer)
8-K - BIOGEN INC. (0000875045) (Filer)
10-Q - BIOGEN INC. (0000875045) (Filer)
Sage Therapeutics Inc. (NASDAQ:SAGE) and Biogen Inc. (NASDAQ:BIIB) announced results Wednesday from the Phase 2 KINETIC 2 dose-range study of SAGE-324 (BIIB124) as a potential treatment for essential tremor (ET). The KINETIC 2 Study did not demonstrate a statistically significant dose-response relationship in change from baseline to Day 91 based on the primary endpoint, The Essential Tremor Rating Assessment Scale (TETRAS) Performance Subscale (PS) Item 4 (upper limb) total score. TETRAS is used to quantify the severity of tremors and their impact on daily living activities. Also Read: Neurodegenerative Disorder-Focused Sage Therapeutics Stock Falls On Disappointing Parkinson’s Dat
Ionis Pharmaceuticals Inc (NASDAQ:IONS) released results Monday from the completed multiple ascending dose (MAD) portion of the Phase 1/2 open-label study of ION582 in people with Angelman syndrome (AS). AS is a rare neurodevelopmental disorder caused by a loss of function in the maternal UBE3A gene. It affects an estimated 1 in 21,000 people worldwide. The data demonstrated consistent and encouraging clinical improvement on assessing all functional domains, including communication, cognition, and motor function measures. Also Read: Ionis Pharmaceuticals Reveals Late-Stage Donidalorsen Data, Analyst Says Results Show Competitive Hereditary Angioedema Profile. Overall, 97% of peop
Submission status for BIOGEN INC's drug VUMERITY (ORIG-1) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/12/2024. Application Category: NDA, Application Number: 761347, Application Classification: Type 3 - New Dosage Form
Submission status for BIOGEN INC's drug VUMERITY (SUPPL-17) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/11/2024. Application Category: NDA, Application Number: 211855, Application Classification: Manufacturing (CMC)
Submission status for BIOGEN INC's drug VUMERITY (SUPPL-15) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211855, Application Classification: Labeling
CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- The Biogen Inc. (NASDAQ:BIIB) Board of Directors (the "Board") today announced the appointments of two new independent directors, Lloyd B. Minor, M.D., effective October 1, 2024, and Sir Menelas (Mene) Pangalos, Ph.D., effective January 1, 2025. Dr. Minor is currently the Dean of the Stanford University School of Medicine and Vice President for Medical Affairs at Stanford University, and Prof Sir Pangalos was most recently Executive Vice President of Biopharmaceuticals R&D at AstraZeneca until his retirement in April 2024. "We welcome Lloyd and Mene to our Board as they add significant experience and proven track records in leading R&D
CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced the appointment of Monish Patolawala, currently President and Chief Financial Officer of 3M Company ("3M"), to the Company's Board of Directors (the "Board"), effective January 1, 2024. As an accomplished financial executive, Mr. Patolawala is qualified as an Audit Committee financial expert and may be asked to serve as a member of the Board's Audit Committee. "We are pleased to welcome Monish to the Board as the Company is advancing on its next chapter," said Caroline Dorsa, Chair of the Biogen Board of Directors. "Monish's deep financial expertise and diversified management experience at leadin
CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) announced the appointment of Jane Grogan, Ph.D., as Executive Vice President, Head of Research effective 2 October 2023. Dr. Grogan will be a member of Biogen's Executive Committee reporting to Christopher A. Viehbacher, President and Chief Executive Officer. "Dr. Grogan is a pioneering scientist whose groundbreaking discoveries at Genentech helped pave the way for development of targeted autoimmune and oncology therapies. I believe Jane will be a strong asset to Biogen as we seek to bring a greater number of innovative medicines to market faster and more effectively," said Mr. Viehbacher. "Together with Dr. Pr
SC 13G/A - BIOGEN INC. (0000875045) (Subject)
SC 13G/A - BIOGEN INC. (0000875045) (Subject)
SC 13G/A - BIOGEN INC. (0000875045) (Subject)
4 - BIOGEN INC. (0000875045) (Issuer)
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases (IMDs). "We are very excited about the addition of felzartamab into our pipeline, further strengthening our presence in immunology with a promising late-stage therapeutic candidate being studied in multiple indications," said Priya Singhal, M.D., M.P.H., Head of Development at Biogen. "With the transaction now complete, we will begin working together with our colleagues from HI-Bio on plans to advance felzart
Reata acquisition bolsters Biogen's rare disease portfolio with the addition of SKYCLARYS® (omaveloxolone), the first and only FDA approved treatment for Friedreich's ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) – has completed the acquisition of Reata Pharmaceuticals, Inc. (NASDAQ:RETA), a company focused on developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. As a result of the transaction, Biogen has now acquired SKYCLARYS® (omaveloxolone), as well as other clinical and preclinical pipeline programs. SKYCLARYS®, Reata Pharmaceuticals' lead asset, was approved for the treatment of
SKYCLARYS® recently approved in US as the only treatment indicated for patients with Friedreich's ataxia Proposed acquisition represents meaningful step forward in Biogen's strategy for sustainable growth, adding a highly complementary innovative product in an area of high unmet medical needExpected to be significantly accretive to Biogen's Non-GAAP diluted EPS beginning in 2025Biogen to host investor conference call today at 9:00 a.m. ET. CAMBRIDGE, Mass. and PLANO, Texas, July 28, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) and Reata Pharmaceuticals, Inc. (NASDAQ:RETA) today announced the companies have entered into a definitive agreement under which Biogen has agreed to a